Category Industry Updates

LISTERINE® Launches Oral Care Counts on World Smile Day as Global Oral Disease Cases Reach 3.73 Billion

LISTERINE® Launches Oral Care Counts Initiative to Highlight the Essential Role of Oral Health in Overall Wellbeing LISTERINE® is launching Oral Care Counts, a multiyear education and advocacy initiative designed to raise awareness of the importance of oral health as…

Read MoreLISTERINE® Launches Oral Care Counts on World Smile Day as Global Oral Disease Cases Reach 3.73 Billion

Blue Matter Launches Behavioral Science Center of Excellence to Predict Health Care Decisions in Biopharma

Blue Matter Launches Behavioral Science Center of Excellence to Strengthen Biopharma Market Research and Decision-Making Blue Matter has announced the launch of its Behavioral Science Center of Excellence (BeSci CoE), a specialized capability within the company’s Blue Matter Insights primary…

Read MoreBlue Matter Launches Behavioral Science Center of Excellence to Predict Health Care Decisions in Biopharma

Fresenius Kabi Receives Vizient Pharmacy Strategic Programs Excellence Award

Fresenius Kabi Receives 2026 Vizient Pharmacy Strategic Programs Excellence Award Fresenius Kabi, part of global healthcare company Fresenius, has received the 2026 Pharmacy Strategic Programs Excellence Award from Vizient, a provider-driven healthcare performance improvement company in the United States. The…

Read MoreFresenius Kabi Receives Vizient Pharmacy Strategic Programs Excellence Award

CytoAgents Presents New Preclinical CTO1681 Data at 2026 EADV Congress

CytoAgents Presents Preclinical Data Supporting CTO1681 in Atopic Dermatitis at EADV Congress 2026 CytoAgents, Inc., a clinical-stage biotechnology company developing CTO1681, an oral, steroid-sparing immunomodulator for diseases associated with dysregulated inflammation, has announced the presentation of new preclinical findings evaluating…

Read MoreCytoAgents Presents New Preclinical CTO1681 Data at 2026 EADV Congress

Alnylam’s AMVUTTRA® ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Raise Awareness of ATTR-CM Signs

Alnylam Launches ‘Play by Play’ Initiative to Raise Awareness of ATTR-CM and Support Earlier Diagnosis Alnylam Pharmaceuticals, Inc., a company focused on RNA interference (RNAi) therapeutics, has launched “AMVUTTRA® ‘Play by Play,’” a new U.S. educational initiative designed to raise…

Read MoreAlnylam’s AMVUTTRA® ‘Play by Play’ Initiative Highlights Former Athletes’ Stories to Raise Awareness of ATTR-CM Signs

Asahi Kasei to Consolidate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics

Asahi Kasei Unifies Global Pharmaceutical Operations Under Asahi Kasei Therapeutics Brand Asahi Kasei has announced plans to bring its pharmaceutical businesses in Japan, the United States, Sweden and Germany together under the Asahi Kasei Therapeutics brand, establishing a unified global…

Read MoreAsahi Kasei to Consolidate Global Pharmaceutical Brand Under Asahi Kasei Therapeutics

Canadians Call for More Consistent Breast Cancer Care From Screening to Survivorship

Breast Cancer Canada Survey Highlights Demand for More Consistent and Coordinated Breast Cancer Care Breast Cancer Canada, a national charity focused on advancing breast cancer research and improving outcomes for patients, has released new national survey findings showing strong public…

Read MoreCanadians Call for More Consistent Breast Cancer Care From Screening to Survivorship

Diagnostic Imaging Centers of Texas and VoxNeuro Partner to Advance Patient Care

Diagnostic Imaging Centers of Texas Expands VoxNeuro Collaboration to Enhance Post-Trauma Patient Evaluation Diagnostic Imaging Centers of Texas (DICOT) has announced an expanded collaboration with VoxNeuro Inc. designed to support a more integrated approach to evaluating patients recovering from motor…

Read MoreDiagnostic Imaging Centers of Texas and VoxNeuro Partner to Advance Patient Care

Lōkahi Therapeutics Expands ai2 Pipeline Program Through Pepperdine E2B Collaboration

Lōkahi Therapeutics Expands ai2 Pipeline Program Through Partnership With Pepperdine E2B Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK), has announced a new collaboration with Pepperdine E2B™ (Education to Business) designed to connect graduate-level business education with real-world opportunities…

Read MoreLōkahi Therapeutics Expands ai2 Pipeline Program Through Pepperdine E2B Collaboration

New Data Shows Breast Cancer Index Testing Changed Extended Endocrine Therapy Recommendations for Over 40% of Patients

New Data Shows Breast Cancer Index Testing Influences Extended Endocrine Therapy Decisions Hologic, Inc. and its subsidiary Biotheranostics, Inc. have announced new findings from the Breast Cancer Index (BCI) Registry Study, showing that use of the genomic test resulted in…

Read MoreNew Data Shows Breast Cancer Index Testing Changed Extended Endocrine Therapy Recommendations for Over 40% of Patients